Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis
- PMID: 10648471
- DOI: 10.1016/s0016-5085(00)70225-3
Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis
Abstract
Findings consistent with the hypothesis that increased central opioidergic tone contributes to the pruritus of cholestasis provide a rationale for treating this form of pruritus with opiate antagonists. However, initiation of therapy with an opiate antagonist in a cholestatic patient may precipitate a transient opioid withdrawal-like reaction. A woman with chronic cholestasis and disabling pruritus experienced severe transient opioid withdrawal-like reactions after oral administration of 12.5 and 2 mg naltrexone. Subsequently, naloxone was administered by intravenous infusion. Initially, the infusion rate was low and subtherapeutic. It was gradually increased to a rate known to be effective in inducing opioid antagonism. Oral naltrexone was then reintroduced without any reaction occurring. During the ensuing 12 months, while taking naltrexone, 25 mg daily, the patient has been completely free from pruritus. These observations strongly support the hypothesis that increased central opioidergic tone is a component of the pathophysiology of cholestasis.
Comment in
-
Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy.Gastroenterology. 2001 Sep;121(3):743-4. doi: 10.1053/gast.2001.27714. Gastroenterology. 2001. PMID: 11547785 No abstract available.
Similar articles
-
Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions.QJM. 2002 Aug;95(8):547-52. doi: 10.1093/qjmed/95.8.547. QJM. 2002. PMID: 12145394 Review.
-
Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy.Eur J Gastroenterol Hepatol. 2001 Nov;13(11):1393-4. doi: 10.1097/00042737-200111000-00022. Eur J Gastroenterol Hepatol. 2001. PMID: 11692070
-
Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.J Hepatol. 2002 Dec;37(6):717-22. doi: 10.1016/s0168-8278(02)00318-5. J Hepatol. 2002. PMID: 12445410 Clinical Trial.
-
Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.Gastroenterology. 1997 Oct;113(4):1264-9. doi: 10.1053/gast.1997.v113.pm9322521. Gastroenterology. 1997. PMID: 9322521 Clinical Trial.
-
Naltrexone: a case report of pruritus from an antipruritic.Australas J Dermatol. 1997 Nov;38(4):196-8. doi: 10.1111/j.1440-0960.1997.tb01696.x. Australas J Dermatol. 1997. PMID: 9431714 Review.
Cited by
-
Effect of oral naltrexone on pruritus in cholestatic patients.World J Gastroenterol. 2006 Feb 21;12(7):1125-8. doi: 10.3748/wjg.v12.i7.1125. World J Gastroenterol. 2006. PMID: 16534857 Free PMC article. Clinical Trial.
-
Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip.BMJ Case Rep. 2015 Jan 27;2015:bcr2014207037. doi: 10.1136/bcr-2014-207037. BMJ Case Rep. 2015. PMID: 25628319 Free PMC article.
-
Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.Clin Rev Allergy Immunol. 2005 Apr;28(2):147-57. doi: 10.1385/CRIAI:28:2:147. Clin Rev Allergy Immunol. 2005. PMID: 15879620 Review.
-
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Gut. 2018 Sep;67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. Epub 2018 Mar 28. Gut. 2018. PMID: 29593060 Free PMC article.
-
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.World J Hepatol. 2015 May 8;7(7):926-41. doi: 10.4254/wjh.v7.i7.926. World J Hepatol. 2015. PMID: 25954476 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical